Highland Capital Management, LLC Exelixis, Inc. Transaction History

Highland Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 21, 2021	SELL	$18.39 - $24.8 $1.06 Million - $1.43 Million	-57,565 Closed	0 $0
Q3 2020 Oct 16, 2020	BUY	$20.67 - $26.94 $33,361 - $43,481	1,614 Added 2.88%	57,565 $1.41 Million
Q2 2020 Jul 22, 2020	SELL	$16.46 - $27.42 $71,452 - $119,030	-4,341 Reduced 7.2%	55,951 $1.33 Million
Q1 2020 May 05, 2020	BUY	$14.46 - $21.8 $871,822 - $1.31 Million	60,292 New	60,292 $1.04 Million
Q2 2019 Jul 29, 2019	SELL	$18.93 - $24.75 $1.4 Million - $1.83 Million	-73,960 Closed	0 $0
Q1 2019 Apr 18, 2019	BUY	$19.6 - $24.76 $13,347 - $16,861	681 Added 0.93%	73,960 $1.76 Million
Q4 2018 Jan 16, 2019	BUY	$13.65 - $21.8 $1 Million - $1.6 Million	73,279 New	73,279 $1.44 Million

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.57B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Highland Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Highland Capital Management, LLC with notifications on news.